Calumet Inc Jumps As Wall Street Lifts Price Targets

Calumet Inc stocks have been trading up by 4.33 percent after upbeat earnings and strong guidance boosted investor confidence.

Weekly Update Aug 24 – Aug 28, 2026: On Sunday, August 30, 2026 Calumet Inc stock [NASDAQ: CLMT] is trending up by 4.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Materials industry expert:

Analyst sentiment – positive

Calumet (CLMT) remains a high-operating-leverage, transition story with improving but still fragile fundamentals. EBITDA margin at 5.7% on $4.1B LTM revenue is modest, while EBIT and net margins remain negative, reflected in ROA of roughly -5% and deeply negative equity (BVPS -$12.94). Cash generation is better than earnings: Q2 operating cash flow of $92M and FCF of $54M against net loss of $96M signal meaningful non-cash and working-capital effects. Leverage is heavy (LT debt ~$2.2B, current ratio 0.8, interest coverage 1.3x), but recent debt paydown and positive FCF demonstrate credible, though still early, deleveraging momentum.

Technically, CLMT is consolidating at the high end of its recent range after a sharp re-rating. The weekly data show price pinned between roughly $45.75 and $47.80, with repeated closes in the mid‑$47s and shallow intraday dips quickly bought, indicating firm demand and tight supply near new highs. Recent 5‑minute candles show orderly intraday pullbacks on lighter volume and pushes higher on stronger volume, confirming a constructive, near-term uptrend. Actionable level: $45.50–46.00 is the key support zone; a pullback into that band is a buy zone with a tight stop below $45.

Fundamentally, CLMT now trades as a deleveraging-plus-renewables re‑rating story versus Materials and Chemicals peers. Street targets have reset sharply higher (UBS/GS/BoA/TD Cowen all at $40–47) on evidence of improving specialty margins, Q2 revenue beat, and clear debt reduction plus Montana Renewables MaxSAF growth. Still, negative GAAP earnings, subscale balance sheet, and execution risk on SAF ramp keep it riskier than integrated chemicals peers. Base case: maintain a constructive stance with a 6–12 month upside target of $52 and strong support at $45, resistance near $50.

Quick Financial Overview

Calumet Inc and CLMT are trading in a firm uptrend, with recent weekly closes clustering around the mid-$40s. The stock printed a tight series between about $45.77 and $47.79 across recent days, with the latest close near $47.75. Intraday, a 5‑minute candle showed a strong range from roughly $46.26 to $48.38 before settling back at $47.75, pointing to active two-way trading but clear demand on dips.

On the income side, CLMT is still loss-making, but the trend is improving. Q2 revenue hit $1.45B, well ahead of the roughly $1.12B consensus, with EPS narrowing to -$1.09 from -$1.70 year over year. Gross margin sits around 6.6%, and EBITDA margin is about 5.7%, so this is a thin-margin, high-throughput business, but the direction of change is positive.

Balance-sheet risk remains the key overhang. Total revenue over the last year is about $4.14B, with a price-to-sales ratio near 0.91, suggesting the market is not paying a premium despite the recent run. Long-term debt is roughly $2.23B, equity is negative, and working capital is around -$194M, so leverage is heavy. That said, CLMT generated about $92.3M in operating cash flow and $54M in free cash flow in the latest quarter, and management has already reduced debt by $115M, which supports the analyst narrative around accelerated deleveraging.

Conclusion

Calumet Inc is in the middle of a re-rating driven by better numbers, but the story is still high risk. Q2 revenue of $1.45B beat expectations and CLMT narrowed its loss, while free cash flow turned solid enough for management to pay down $115M of debt and still fund growth at Montana Renewables. Price action near $47–$48 shows that buyers are willing to support the stock on dips, but the intraday swings highlight that this is not a quiet name.

On the other side of the ledger, CLMT still carries more than $2B of long-term debt, negative equity, and thin margins, which is why Goldman Sachs, UBS, and TD Cowen all raised price targets but stayed Neutral/Hold. Their targets up to $40–$47, plus Bank of America’s Buy at $45, tell traders that upside exists, but execution on sustainable aviation fuel ramp and continued debt reduction will decide how far the re-rating can go. The upcoming Barclays energy-power conference on 2026/09/10 gives management another chance to tighten the story around specialty products and renewables.

For traders, this is a momentum and catalyst play anchored in improving fundamentals but wrapped in balance-sheet risk. Levels around the mid-$40s now act as a key reference area: sustained closes above there keep the bullish narrative intact, while a breakdown would flag that the rerating may be stalling. In a name like CLMT, where volatility can trigger emotional entries and exits, discipline is crucial. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” As I tell my students, “You do not get paid for being early or late, you get paid for trading the inflection — and in CLMT, that inflection is where rising cash flow meets heavy debt.””,”scores”:{“risk-level”:”high”},”trade”:”true

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks